Gender-related issues in the pharmacology of new anti-obesity drugs
Gender-related issues in the pharmacology of new anti-obesity drugs
复制标题
DOI：
10.1111/obr.12805
复制
发表时间：
2019-03-01
期刊：
影响因子：
8.9
通讯作者：
Colao, Annamaria
中科院分区：
文献类型：
--
作者：
Cataldi, Mauro;Muscogiuri, Giovanna;Colao, Annamaria
四种新药-利拉鲁肽，氯卡色林，安非他酮/纳洛酮，和芬特明/托吡酯-最近已被添加到用于肥胖治疗的药理学武器库中，并可能代表管理这种流行病的重要工具。为了达到令人满意的抗肥胖目标，这些新药的使用应进行优化，并根据特定的患者亚群进行调整，如有必要，还应进行剂量调整。在本综述中，我们认为性别可能是影响新的减肥药活性的因素之一，因为药代动力学和药效学因素。尽管来自上市前临床研究的证据表明，这些新药中的任何一种都不需要根据性别调整剂量，但这些研究并非专门设计用于识别性别相关差异。这一观察结果以及支持性别二态反应假说的强大理论背景，强烈呼吁迫切需要这些新的肥胖药物药理学中性别相关差异的新的真实数据。
Four new medicines-liraglutide, lorcaserin, bupropion/naltrexone, and phentermine/topiramate-have been recently added to the pharmacological arsenal for obesity treatment and could represent important tools to manage this epidemic disease. To achieve satisfactory anti-obesity goals, the use of these new medicines should be optimized and tailored to specific patient subpopulations also by applying dose adjustments if needed. In the present review, we posit that gender could be among the factors influencing the activity of the new obesity drugs both because of pharmacokinetic and pharmacodynamic factors. Although evidence from premarketing clinical studies suggested that no dose adjustment by gender is necessary for any of these new medicines, these studies were not specifically designed to identify gender-related differences. This observation, together with the strong theoretical background supporting the hypothesis of a gender-dimorphic response, strongly call upon an urgent need of new real-life data on gender-related difference in the pharmacology of these new obesity drugs.